The R71G BRCA1 is a founder Spanish mutation and leads to aberrant splicing of the transcript
- PMID: 11385711
- DOI: 10.1002/humu.1136
The R71G BRCA1 is a founder Spanish mutation and leads to aberrant splicing of the transcript
Abstract
In a BRCA1 screening in familial breast cancer carried out in different centres in Spain, France, and United Kingdom, a missense mutation 330A>G which results in a Arg to Gly change at codon 71 (R71G) was independently identified in 6 families, all of them with Spanish ancestors. This residue coincides with the -2 position of the exon 5 donor splice site. We further investigated the effect of this base substitution on the splicing of BRCA1 mRNA. The sequence analysis of the cDNA indicated that 22 bp of exon 5 were deleted, creating with the first bases of exon 6 a termination codon at position 64, which results in a truncated protein. The BRCA1 haplotype of the R71G carrier patients and Spanish controls was analysed by use of six microsatellites located within or near BRCA1. Our results are consistent with the possibility that these families shared a common ancestry with BRCA1 R71G being a founder mutation of Spanish origin.
Copyright 2001 Wiley-Liss, Inc.
Similar articles
-
Analysis of BRCA1 and BRCA2 genes in Spanish breast/ovarian cancer patients: a high proportion of mutations unique to Spain and evidence of founder effects.Hum Mutat. 2003 Oct;22(4):301-12. doi: 10.1002/humu.10260. Hum Mutat. 2003. PMID: 12955716
-
A low frequency of non-founder BRCA1 mutations in Ashkenazi Jewish breast-ovarian cancer families.Hum Mutat. 2002 Nov;20(5):352-7. doi: 10.1002/humu.10123. Hum Mutat. 2002. PMID: 12402332
-
A high proportion of DNA variants of BRCA1 and BRCA2 is associated with aberrant splicing in breast/ovarian cancer patients.Clin Cancer Res. 2010 Mar 15;16(6):1957-67. doi: 10.1158/1078-0432.CCR-09-2564. Epub 2010 Mar 9. Clin Cancer Res. 2010. PMID: 20215541
-
Identification of germline 185delAG BRCA1 mutations in non-Jewish Americans of Spanish ancestry from the San Luis Valley, Colorado.Cancer. 2003 Aug 1;98(3):597-602. doi: 10.1002/cncr.11533. Cancer. 2003. PMID: 12879478 Review.
-
BRCA1 exon 11 alternative splicing, multiple functions and the association with cancer.Biochem Soc Trans. 2012 Aug;40(4):768-72. doi: 10.1042/BST20120140. Biochem Soc Trans. 2012. PMID: 22817731 Review.
Cited by
-
Prevalence of BRCA1 and BRCA2 pathogenic and likely pathogenic variants in non-selected ovarian carcinoma patients in Brazil.BMC Cancer. 2019 Jan 3;19(1):4. doi: 10.1186/s12885-018-5235-3. BMC Cancer. 2019. PMID: 30606148 Free PMC article.
-
The BRCA1 variant p.Ser36Tyr abrogates BRCA1 protein function and potentially confers a moderate risk of breast cancer.PLoS One. 2014 Apr 2;9(4):e93400. doi: 10.1371/journal.pone.0093400. eCollection 2014. PLoS One. 2014. PMID: 24695549 Free PMC article.
-
Functional differences among BRCA1 missense mutations in the control of centrosome duplication.Oncogene. 2012 Feb 9;31(6):799-804. doi: 10.1038/onc.2011.271. Epub 2011 Jul 4. Oncogene. 2012. PMID: 21725363 Free PMC article.
-
Variantes genéticas recurrentes y priorización de variantes de significado clínico desconocido asociadas al síndrome de cáncer de mama y ovario hereditario en familias de la Región de Murcia.Adv Lab Med. 2023 Jul 10;4(3):288-297. doi: 10.1515/almed-2023-0032. eCollection 2023 Sep. Adv Lab Med. 2023. PMID: 38075173 Free PMC article. Spanish.
-
The prevalence of BRCA1 and BRCA2 mutations among young Mexican women with triple-negative breast cancer.Breast Cancer Res Treat. 2015 Apr;150(2):389-94. doi: 10.1007/s10549-015-3312-8. Epub 2015 Feb 26. Breast Cancer Res Treat. 2015. PMID: 25716084 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous